EGFR-TKIs耐药与EGFR突变非小细胞肺癌中PD-L1表达的研究进展  

Research Progress of EGFR-TKIs Resistance and PD-L1 Expression in EGFR-Mutant Non-Small Cell Lung Cancer

作　　者：温雅婷 高俊珍[2] 

机构地区：[1]内蒙古医科大学研究生院,内蒙古 呼和浩特 [2]内蒙古医科大学附属医院呼吸与危重症医学科,内蒙古 呼和浩特

出　　处：《临床医学进展》2024年第1期183-189,共7页Advances in Clinical Medicine

摘　　要：表皮生长因子受体酪氨酸激酶抑制剂可改善EGFR突变的非小细胞肺癌患者生存期。然而部分患者表现出原发性/获得性耐药,疗效间存在差异。PD-L1表达水平可作为免疫检查点抑制剂治疗的预测性生物标志物,PD-1/PD-L1抑制剂已被批准用于晚期NSCLC的一线治疗。研究表明,部分EGFR突变NSCLC患者免疫治疗效果欠佳,可能与其肿瘤微环境相关。本文就EGFR突变患者的肿瘤微环境与PD-L1的联系、PD-L1在EGFR突变的非小细胞肺癌患者中表达率及与EGFR-TKIs疗效等方面的研究进行综述。Epidermal growth factor receptor tyrosine kinase inhibitors improve survival in patients with EGFR-mutated non-small cell lung cancer. However, some patients exhibit primary/acquired re-sistance and efficacies are different. PD-L1 expression level can be used as a predictive biomarker for treatment with immune checkpoint inhibitors, and PD-1/PD-L1 inhibitors have been approved for first-line treatment of advanced NSCLC. Studies have shown that some EGFR mutant NSCLC pa-tients have poor immunotherapy outcomes, which may be related to their tumor microenvironment. In this article, we review the studies on the association between tumor microenvironment and PD-L1 in patients with EGFR mutations, the expression rate of PD-L1 in patients with EGFR- mutated NSCLC, and the efficacy with EGFR-TKIs.

关 键 词：EGFR 肿瘤微环境 PD-L1 EGFR-TKIs耐药 信号通路 

分 类 号：R73[医药卫生—肿瘤]